Anil Nair is the Vice President of In Silico Discovery and joined the OmniAb team through Ligand Pharmaceuticals’ Icagen acquisition in 2020. He leads and coordinates all activities in computational chemistry, medicinal chemistry and in silico drug discovery. Dr. Nair joined Icagen, Inc. in 2016 following a successful career at Sanofi, which he began in 2001. At Sanofi, Dr. Nair had positions of increasing responsibility including Global Coordinator for Structure, Design and Informatics. Dr. Nair received his PhD in Quantum Chemistry at Banaras Hindu University and completed a postdoctoral fellowship at the University of Missouri.
